Listed

HealthLynked Corp: Form 10-Q for the period ended Sep 30, 2024

Filed with the SEC on Nov 14, 2024 and accepted by EDGAR at Nov 14, 2024, 16:01 ET.

Share

Management's discussion and analysis

As filed, 49,311 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Forward-Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Item 1A. Risk Factors” included in our most recent Annual Report on Form 10-K. All amounts in this report are in U.S. dollars, unless otherwise noted.

Overview

General

HealthLynked Corp. (the “Company,” “we,” “our,” or “us”) was incorporated in the State of Nevada on August 4, 2014. We currently operate in three distinct divisions:

  • Health Services Division: This division includes a diverse range of practices in Naples Women’s Center (“NWC”), offering comprehensive Obstetrics and Gynecology services; Naples Center for Functional Medicine (“NCFM”), which provides personalized and integrative healthcare solutions; Bridging the Gap Physical Therapy (“BTG”) in Bonita Springs, specializing in manual therapy techniques to expedite recovery and manage pain without the need for medications or surgery; and Aesthetic Enhancements Unlimited (“AEU”), which focuses on minimally and non-invasive cosmetic services.
  • Digital Healthcare Division: At the forefront of healthcare innovation, this division develops and manages an advanced online concierge medical service. The HealthLynked Network facilitates efficient management of medical records and care, allowing seamless patient appointment scheduling, comprehensive telemedicine services, and a cloud-based system for medical information and records management. It also supports physicians in expanding their practices and acquiring new patients through our robust online scheduling system.
  • Medical Distribution Division: MedOffice Direct LLC (“MOD”), a part of this division, operates as a virtual distributor of discounted medical supplies to consumers and medical practices nationwide, ensuring timely and cost-effective delivery.

Critical accounting policies and significant judgments and estimates

For a discussion of our critical accounting policies, see Note 2, “Significant Accounting Policies,” in the Notes to the condensed consolidated financial statements.

Results of Operations

Comparison of Three months ended September 30, 2024 and 2023

The following table summarizes the changes in our results of operations for the three months ended September 30, 2024 compared with the three months ended September 30, 2023:

Three Months Ended September 30, 2024 2023 Change $%
Patient service revenue, net $522,795 $1,271,466 $(748,671) -59%
Subscription revenue 32,367 18,574 13,793 74%
Product revenue 34,962 42,475 (7,513) -18%
Total revenue 590,124 1,332,515 (742,391) -56%
Operating Expenses and Costs
Practice salaries and benefits 449,759 772,416 (322,657) -42%
Other practice operating expenses 349,467 529,067 (179,600) -34%
Cost of product revenue 31,674 40,820 (9,146) -22%
Selling, general and administrative expenses 631,828 767,705 (135,877) -18%
Depreciation and amortization 82,743 87,392 (4,649) -5%
Impairment loss 716,000 319,958 396,042 124%
Loss from operations (1,671,347) (1,184,843) (486,504) 41%
Other Income (Expenses)
Loss on extinguishment of debt 2,580 --- 2,580 *
Change in fair value of debt 65,344 --- 65,344 *
Gain from expiration of liability classified equity instruments --- 92,641 (92,641) -100%
Amortization of original issue discounts on notes payable (322,141) (132,155) (189,986) 144%
Gain from realization of contingent sale consideration receivable --- 1,075,857 (1,075,857) -100%
Change in fair value of contingent acquisition consideration 1,478 4,819 (3,341) -69%
Interest expense (49,033) (17,689) (31,344) 177%
Total other income (expenses) (301,772) 1,023,473 (1,325,245) -129%
Loss from continuing operations (1,973,119) (161,370) (1,811,749) 1123%
Loss from operations of discontinued operations
Loss from operations of discontinued operations --- (13,554) 13,554 -100%
Gain (loss) on discontinued operations --- (13,554) 13,554 -100%
Net loss $(1,973,119) $(174,924) $(1,798,195) 1028%

* - Denotes line item on statement of operations for which there was no corresponding activity in the same period of prior year.

Revenue

Patient service revenue decreased by $748,671, or 59% year-over-year, from $1,271,466 in the three months ended September 30, 2023, to $522,795 in the three months ended September 30, 2024, primarily as a result of (i) a 65% year-over-year decrease at our NCFM practice of $677,092 due to changes in clinical staffing that saw the departure of three physicians in 2023, two of which have been replaced, (ii) a 45% decrease at our NWC practice facility of $66,434 due to the departure of a half-time physician, and (iii) an 88% year-over-year decrease at our AEU practice of $26,360 due to the departure of our primary half-time physician and attrition from the practice, offset by (iv) a 43% increase of $21,214 at our BTG practice. The reduction in revenue was offset in part by a corresponding designed reduction in practice operating costs as described below in the fluctuation of “Practice salaries and benefits” and “Other practice operating costs,” which declined by a combined $502,257 from the three months ended September 30, 2023 to the same period of 2024. While we plan for patient service revenue to increase in future periods from levels realized in the three months ended September 30, 2024 as we plan to add additional physicians and continue patient marketing and retention efforts, there is no guarantee that such increases will occur.

Subscription revenue in the three months ended September 30, 2024 increased by $13,793, or 74% year-over-year, to $32,367, from $18,574, due primarily to an increase in HealthLynked Network paid subscriptions that were paired with NCFM membership contracts compared to the same period in 2023.

Product revenue was $34,962 in the three months ended September 30, 2024, compared to $42,475 in the three months ended September 30, 2023, a decrease of $7,513, or 18%. Product revenue was earned by the Medical Distribution Division, comprised of the operations of MOD, which decreased due to reduced marketing efforts and demand for our products at our offered price points.

Operating Expenses and Costs

Practice salaries and benefits decreased by $322,657, or 42%, to $449,759 in the three months ended September 30, 2024, compared to $772,416 in the three months ended September 30, 2023, primarily as a result of focused cost reduction efforts at all of our practices starting in mid-2023 and continuing through mid-2024.

Other practice operating costs decreased by $179,600 or 34%, to $349,467 in the three months ended September 30, 2024 from $529,067 in the three months ended September 30, 2023, primarily as a result of focused cost reduction efforts at all of our practices starting in mid-2023 and continuing through mid-2024.

Cost of product revenue was $31,674 in the three months ended September 30, 2024, a decrease of $9,146, or 22%, compared to $40,820 in the same period of 2023, corresponding to the decline in product sales for the period compared to the same period in the prior year.

Selling, general and administrative costs decreased by $135,877, or 18%, to $631,829 in the three months ended September 30, 2024 compared to $767,705 in the three months ended September 30, 2023, primarily due to lower payroll, legal and accounting costs, and stock-based compensation costs.

Depreciation and amortization in the three months ended September 30, 2024 decreased by $4,649, or 5%, to $82,743 compared to $87,392 in the three months ended September 30, 2023, primarily as a result of certain fixed asset reaching the end of their depreciable lives during 2023.

During the three months ended September 30, 2024, the Company determined that triggering events had occurred that required an impairment assessment of the NCFM Medical Database. The triggering events included (i) a material decline in revenue during third quarter 2024, including a 65% decline compared to the three months ended September 30, 2023 and a 35% decline compared to the preceding three month period ended June 30, 2024, (ii) substantial operating losses and negative cash flows generated from the practice during the three months ended September 30, 2024 for the first time since its acquisition, and (iii) substantial downsizing of the practice personnel and overhead. We determined that the carrying amount of the reporting unit, which consists of the NCFM practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $716,000 to adjust carrying value of the NCFM Medical Database to its estimated fair value of $-0- in the three months ended September 30, 2024. During the three months ended September 30, 2023, we determined that triggering events had occurred that required impairment assessments of goodwill related to our AEU business. The triggering events included (i) a material decline in revenue during third quarter 2023, and (ii) an inability of the business to achieve profitability since its acquisition. We determined that the carrying amount of the reporting unit, which consists of the AEU practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $319,958 to adjust carrying value of AEU goodwill to its estimated fair value of $-0- in the three months ended September 30, 2023.

Loss from operations increased by $486,504, or 41%, to $1,671,347 in the three months ended September 30, 2024 compared to $1,184,843 in the three months ended September 30, 2023, primarily as a result of higher impairment charge along with decreased revenue in 2024, offset in part by reduced practice operating costs and corporate overhead costs.

Other Income (Expenses)

Loss on extinguishment of debt in the three months ended September 30, 2024 was $2,580. Loss on extinguishment of debt in 2024 resulted from the net impact of the extension of the maturity date of two maturing note payable to Dr. Dent in exchange for the issuance of warrants. There were no such losses in the three months ended September 30, 2023.

Gains from the change in fair value of debt was $65,344 in the three months ended September 30, 2024 related to three notes payable to Dr. Michael Dent that were recorded at fair value following extension of the maturity dates of the notes. These notes are revalued at their fair value at the end of each period, with the changes recorded as gains or losses from the change in fair value of debt. There were no such gains or losses in the three months ended September 30, 2023.

Gain from expiration of liability classified equity instruments was $92,641 in the three months ended September 30, 2023 and resulted from the expiration of liability-classified warrants issued in 2020. There were no such gains or losses in the three months ended September 30, 2024.

Amortization of original issue and debt discounts on notes payable and convertible notes in the three months ended September 30, 2024 was $322,141, an increase of $189,986, or 144%, compared to $132,155 in the three months ended September 30, 2023. Amortization of discounts arose from original issue discounts on notes payable, warrants attached to notes payable, and beneficial conversion features in convertible notes payable. The increase was due to higher notes payable balances and larger equity-based and original issue discounts offered for new notes payable, primarily to our CEO, Dr. Dent, and therefore larger corresponding amortizable discount balances in 2024 compared to 2023.

Gain from realization of contingent sale consideration receivable was $-0-, a decrease of $1,075,857, or 100% compared to a gain of $1,075,857 in the three months ended September 30, 2023. The gain in 2023 resulted from actual proceeds received during the period from contingent sale consideration related to the sale of AHP in excess of the amount estimated to be received at the time of the sale in January 2023. Receipts during the three months ended September 30, 2023 included $450,000 gross ($360,000 net) in Incremental Cash Consideration and $1,873,993 gross ($1,186,231 net) from the 2022 MSSP Consideration. There were no receipts of such consideration during the three months ended September 30, 2024.

Gain from the change in fair value of contingent acquisition consideration decreased by $3,341, or 69%, to $1,478 in the three months ended September 30, 2024, compared to $4,819 in the three months ended September 30, 2023. These gains relate to the fourth and final year of the MOD earnout, which is based on the performance of our Medical Distribution Division in calendar year 2024 and is projected to have no required payout based on the 2024 performance of the MOD business.

Interest expense increased by $31,344, or 177%, to $49,033 for the three months ended September 30, 2024, compared to $17,689 in the three months ended September 30, 2023, due to an increase in interest-bearing notes payable to related parties and third parties during 2024, primarily in the form of new notes and convertible notes payable to Dr. Dent.

Total other income (expenses) increased by $1,325,425, or 129%, to net expense of $301,772 in the three months ended September 30, 2024 compared to net income of $1,023,473 in the three months ended September 30, 2023. The change was primarily a result of a gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in 2023, offset by higher debt-related interest and discount amortization charges in 2024 corresponding to higher debt balances with larger initial fees and discounts.

Loss from continuing operations increased by $1,811,749, or 1,123%, to $1,973,119 in the three months ended September 30, 2024, compared to $161,370 in the three months ended September 30, 2023. The increased loss was due primarily to a $1,075,857 gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in the three months ended September 30, 2023, higher impairment charges and a decrease in patient service revenue in 2024, offset in part by reduced practice operating costs and corporate overhead costs.

Gain (loss) from operations of discontinued operations

As a result of the AHP Sale on January 17, 2023, our ACO/MSO Division was classified as discontinued operations in the accompanying consolidated statement of operations for the three months ended September 30, 2024 and 2023. Loss from operations of discontinued operations decreased by $13,554, or 100%, from $13,554 in the three months ended September 30, 2023 to $-0- in the three months ended September 30, 2024. The loss in 2023 reflects winding down costs of the discontinued operation after the sale on January 17, 2023. No revenue or costs were incurred related to the business in the three months ended September 30, 2024.

Net loss

Net loss increased by $1,798,195, or 1,028%, to $1,973,119 in the three months ended September 30, 2024, compared to $174,924 in the three months ended September 30, 2023, due primarily to a $1,075,857 gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in the three months ended September 30, 2023, higher impairment charges and a decrease in patient service revenue in 2024, offset in part by reduced practice operating costs and corporate overhead costs.

Comparison of Nine months ended September 30, 2024 and 2023

The following table summarizes the changes in our results of operations for the nine months ended September 30, 2024 compared with the nine months ended September 30, 2023:

Nine Months Ended September 30, 2024 2023 Change $%
Patient service revenue, net $2,249,579 $4,602,081 $(2,352,502) -51%
Subscription revenue 48,161 54,050 (5,889) -11%
Product revenue 91,694 135,034 (43,340) -32%
Total revenue 2,389,434 4,791,165 (2,401,731) -50%
Operating Expenses and Costs
Practice salaries and benefits 1,546,806 2,635,065 (1,088,259) -41%
Other practice operating expenses 1,221,272 1,799,530 (578,258) -32%
Cost of product revenue 86,976 107,277 (20,301) -19%
Selling, general and administrative expenses 2,492,740 2,705,142 (212,402) -8%
Depreciation and amortization 254,514 263,762 (9,248) -4%
Impairment loss 716,000 319,958 396,042 124%
Loss from operations (3,928,874) (3,039,569) (889,305) 29%
Other Income (Expenses)
Loss on extinguishment of debt (167,647) (88,932) (78,715) 89%
Change in fair value of debt 93,244 --- 93,244 *
Gain from expiration of liability classified equity instruments --- 92,641 (92,641) -100%
Amortization of original issue discounts on notes payable (801,762) (324,204) (477,558) 147%
Gain from realization of contingent sale consideration receivable --- 1,090,857 (1,090,857) -100%
Change in fair value of contingent acquisition consideration 2,189 9,183 (6,994) -76%
Interest expense (98,423) (68,194) (30,229) 44%
Total other income (expenses) (972,399) 711,351 (1,683,750) -237%
Loss from continuing operations (4,901,273) (2,328,218) (2,573,055) 111%
Gain (loss) from operations of discontinued operations
Loss from operations of discontinued operations --- (72,295) 72,295 -100%
Gain from disposal of discontinued operations --- 2,674,069 (2,674,069) -100%
Gain (loss) on discontinued operations --- 2,601,774 (2,601,774) -100%
Net income (loss) $(4,901,273) $273,556 $(5,174,829) -1892%

* - Denotes line item on statement of operations for which there was no corresponding activity in the same period of prior year.

Revenue

Patient service revenue decreased by $2,352,502, or 51% year-over-year, from $4,602,081 in the nine months ended September 30, 2023, to $2,249,579 in the nine months ended September 30, 2024, primarily as a result of (i) a 54% year-over-year decrease at our NCFM practice of $1,929,275 due to changes in clinical staffing that saw the departure of three physicians in 2023, two of which have been replaced, (ii) a 92% year-over-year decrease at our AEU practice of $243,251 due to the departure of our primary physician and attrition from the practice, and (iii) a 42% decrease at our NWC practice facility of $228,274, offset by (iv) 22% increase of $48,299 at our BTG practice. The reduction in revenue was offset in part by a corresponding designed reduction in practice operating costs as described below in the fluctuation of “Practice salaries and benefits” and “Other practice operating costs,” which declined by a combined $1,666,517 from the nine months ended September 30, 2023 to the same period of 2024. While we plan for patient service revenue to increase in future periods from levels realized in the nine months ended September 30, 2024 as we plan to add additional physicians and continue patient marketing and retention efforts, there is no guarantee that such increases will occur.

Subscription revenue in the nine months ended September 30, 2024 decreased by $5,889, or 11% year-over-year, to $48,161, from $54,050, due primarily to a decrease in HealthLynked Network paid subscriptions that were paired with NCFM membership contracts.

Product revenue was $91,694 in the nine months ended September 30, 2024, compared to $135,034 in the nine months ended September 30, 2023, a decrease of $43,340, or 32%. Product revenue was earned by the Medical Distribution Division, comprised of the operations of MOD, which decreased due to decreased marketing efforts and demand for our products at our offered price points.

Operating Expenses and Costs

Practice salaries and benefits decreased by $1,088,259, or 41%, to $1,546,806 in the nine months ended September 30, 2024, compared to $2,635,065 in the nine months ended September 30, 2023, primarily as a result of focused cost reduction efforts at all of our practices starting in mid-2023 and continuing through mid-2024.

Other practice operating costs decreased by $578,258 or 32%, to $1,221,272 in the nine months ended September 30, 2024 from $1,799,530 in the nine months ended September 30, 2023, primarily as a result of focused cost reduction efforts at all of our practices starting in mid-2023 and continuing through mid-2024.

Cost of product revenue was $86,976 in the nine months ended September 30, 2024, a decrease of $20,301, or 19%, compared to $107,277 in the same period of 2023, corresponding to the decline in product sales for the period compared to the same period in the prior year.

Selling, general and administrative costs decreased by $212,402, or 8%, to $2,492,740 in the nine months ended September 30, 2024 compared to $2,705,142 in the nine months ended September 30, 2023, primarily due to lower consulting and other overhead costs in our corporate function resulting from focused cost cutting efforts ,as well as lower network-related fees.

Depreciation and amortization in the nine months ended September 30, 2024 decreased by $9,248, or 4%, to $254,514 compared to $263,762 in the nine months ended September 30, 2023, primarily as a result of certain fixed asset reaching the end of their depreciable lives during 2023.

During the nine months ended September 30, 2024, the Company determined that triggering events had occurred that required an impairment assessment of the NCFM Medical Database. The triggering events included (i) a material decline in revenue during third quarter 2024, including a 65% decline compared to the three months ended September 30, 2023 and a 35% decline compared to the preceding three month period ended June 30, 2024, (ii) substantial operating losses and negative cash flows generated from the practice during the three months ended September 30, 2024 for the first time since its acquisition, and (iii) substantial downsizing of the practice personnel and overhead. We determined that the carrying amount of the reporting unit, which consists of the NCFM practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $716,000 to adjust carrying value of the NCFM Medical Database to its estimated fair value of $-0- in the three months ended September 30, 2024. During the nine months ended September 30, 2023, we determined that triggering events had occurred that required impairment assessments of goodwill related to our AEU business. The triggering events included (i) a material decline in revenue during third quarter 2023, and (ii) an inability of the business to achieve profitability since its acquisition. We determined that the carrying amount of the reporting unit, which consists of the AEU practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $319,958 to adjust carrying value of AEU goodwill to its estimated fair value of $-0- in the three months ended September 30, 2023.

Loss from operations increased by $889,305, or 29%, to $3,298,874 in the nine months ended September 30, 2024 compared to $3,039,569 in the nine months ended September 30, 2023, primarily as a result of decreased revenue and increased impairment charges in 2024, offset in part by reduced practice operating costs and corporate overhead costs.

Other Income (Expenses)

Loss on extinguishment of debt in the nine months ended September 30, 2024 was $167,649, compared to a loss of $88,932 in the nine months ended September 30, 2023. Loss on extinguishment of debt in 2023 resulted from early repayment of notes payable to our CEO and extension of notes payable to our CEO and CFO. Loss on extinguishment of debt in 2024 resulted from two maturing notes payable to Dr. Dent refinanced with new convertible notes payable in the same amount and the extension of the maturity date of three additional notes payable to Dr. Dent.

Gains from the change in fair value of debt was $93,244 in the nine months ended September 30, 2024 related to three notes payable to Dr. Michael Dent that were recorded at fair value following extension of the maturity dates of the notes. These notes are revalued at their fair value at the end of each period, with the changes recorded as gains or losses from the change in fair value of debt. There were no such gains or losses in the nine months ended September 30, 2023.

Gain from expiration of liability classified equity instruments was $92,641 in the nine months ended September 30, 2023 and resulted from the expiration of liability-classified warrants issued in 2020. There were no such gains or losses in the three months ended September 30, 2024.

Amortization of original issue and debt discounts on notes payable and convertible notes in the nine months ended September 30, 2024 was $801,762, an increase of $477,558, or 147%, compared to $324,204 in the nine months ended September 30, 2023. Amortization of discounts arose from original issue discounts on notes payable, warrants attached to notes payable, and beneficial conversion features in convertible notes payable. The increase was due to higher notes payable balances and larger equity-based and original issue discounts offered for new notes payable, and therefore larger corresponding amortizable discount balances, in 2024 compared to 2023.

Gain from realization of contingent sale consideration receivable was $-0- in the nine months ended September 30, 2024, a decrease of $1,090,857, or 100% compared to a gain of $1,090,857 in the nine months ended September 30, 2023. The gain in 2023 resulted from actual proceeds received during the period from contingent sale consideration related to the sale of AHP in excess of the amount estimated to be received at the time of the sale in January 2023. Receipts during the nine months ended September 30, 2023 included $1,750,000 gross ($1,540,000 net) in Incremental Cash Consideration and $1,873,993 gross ($1,186,231 net) from the 2022 MSSP Consideration. There were no receipts of such consideration during the nine months ended September 30, 2024.

Gain from the change in fair value of contingent acquisition consideration decreased by $6,994, or 76%, to a gain of $2,189 in the nine months ended September 30, 2024, compared to a gain of $9,183 in the nine months ended September 30, 2023. These charges relate to the fourth and final year of the MOD earnout, which is based on the performance of our Medical Distribution Division in calendar year 2024 and is expected to have no required payout.

Interest expense increased by $30,229, or 44%, to $98,423 for the nine months ended September 30, 2024, compared to $68,194 in the nine months ended September 30, 2023, due to an increase in interest-bearing notes payable to related parties and third parties during 2024, primarily in the form of new notes and convertible notes payable to Dr. Dent.

Total other income (expenses) increased by $1,683,750, or 237%, to net expense of $972,399 in the nine months ended September 30, 2024 compared to net income of $711,351 in the nine months ended September 30, 2023. The change was primarily a result of a $1,090,857 gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in 2023 and higher debt-related interest and discount amortization charges in 2024 corresponding to higher debt balances with larger initial fees and discounts.

Loss from continuing operations increased by $2,573,055, or 111%, to $4,901,273 in the nine months ended September 30, 2024, compared to $2,328,218 in the nine months ended September 30, 2023. The increased loss was due primarily to a decrease in revenue, a $1,090,857 gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in 2023, higher impairment charges and increased financing related other expenses, offset in part by reduced practice operating costs and corporate overhead costs.

Gain (loss) from operations of discontinued operations

As a result of the AHP Sale on January 17, 2023, our ACO/MSO Division was classified as discontinued operations in the accompanying consolidated statement of operations for the nine months ended September 30, 2024 and 2023. Loss from operations of discontinued operations decreased by $72,295, or 100%, from $72,295 in the nine months ended September 30, 2023 to $-0- in the nine months ended September 30, 2024. The loss in 2023 reflects winding down costs of the discontinued operation after the sale on January 17, 2023. No revenue or costs were incurred related to the business in the nine months ended September 30, 2024.

Effective January 17, 2023, we completed the AHP Sale, at which time we discontinued the operations of CHM and ceased to have a controlling financial interest in AHP. In connection with the AHP Sale, as of January 17, 2023, we recognized the fair value of consideration received and receivable from the AHP Sale, recognized an indemnification liability related to potential claims resulting from the AHP Sale, derecognized the carrying value of assets and liabilities transferred to the Buyer or otherwise derecognized in connection with in the AHP Sale, and recorded a gain on sale for the excess of consideration received over carrying value of assets derecognized and liabilities recognized. Accordingly, we recorded a gain from disposal of AHP in the amount of $2,674,069 in the nine months ended September 30, 2023.

Net income (loss)

Net income (loss) decreased by $5,174,829, or 1,892%, to a net loss of ($4,901,273) in the nine months ended September 30, 2024, compared to net income of $273,556 in the nine months ended September 30, 2023, primarily as a result of (i) the gain from disposal of AHP in the amount of $2,674,069 in the nine months ended September 30, 2023 with no corresponding gain in the nine months ended September 30, 2024, (ii) a decrease in revenue and increased impairment charges and financing related other expenses, and (iii) a $1,090,857 gain from realization of contingent sale consideration receivable related to the collection of consideration in the AHP sale in 2023, offset in part by (iv) reduced practice operating costs and corporate overhead costs.

Seasonal Nature of Operations

We do not experience any material seasonality related to any of our continuing operations.

Impairment Analysis

Impairment Reviews

Long-lived assets (including amortizable identifiable intangible assets) or asset groups held for use are tested for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. When such events occur, we compare the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset or asset group to the carrying amount of a long-lived asset or asset group. The cash flows are based on our best estimate of future cash flows derived from the most recent business projections. If this comparison indicates that the asset is not recoverable, we estimate the fair value of the asset group using a discounted cash flow model. An impairment charge is then recorded for any excess carrying value above the estimated fair value of the asset group.

Goodwill is tested for impairment on an annual basis and more often if circumstances indicate that an impairment may be necessary. Goodwill impairment is recognized for any excess carrying value above the estimated fair value of the asset group. Fair value is estimated using the same approach as described above for long-lived asset testing.

The significant assumptions we use in the discounted cash flow models are revenue growth rate, gross profit margins on product sales, operating income margin, and the discount rate used to determine the present value of the cash flow projections. Among other inputs, revenue growth rate and operating income margin are determined by management using historical performance trends, projected performance from existing partnerships, industry data, relevant changes in the reporting unit’s underlying business, and other market trends that may affect the reporting unit. The discount rate is based on the estimated weighted average cost of capital as of the test date of market participants in the industry in which the reporting unit operates. The assumptions used in the discounted cash flow model are subject to significant judgment and uncertainty. Changes in projected revenue growth rates, gross profit margins, projected operating income margins, or estimated discount rates due to uncertain market conditions, losses of key physicians in our Health Services reporting unit, changes in technology, or other factors, could result in one or more of our reporting units with a significant amount of identifiable intangible assets recognizing material impairment charges, which could be material to our results of operations and financial position. Our historical or projected revenues or cash flows may not be indicative of actual future results.

Impairment of NCFM Medical Database – 2024

During the third quarter of 2024, we determined that triggering events had occurred that required an impairment assessment of the NCFM Medical Database. The triggering events included (i) a material decline in revenue during third quarter 2023, including a 65% decline compared to third quarter of 2023 and a 35% decline compared to the second quarter of 2024, (ii) substantial operating losses and negative cash flows generated from the practice for the first time since its acquisition, and (iii) substantial downsizing of the practice personnel and overhead. We do not believe that the levels of revenue and profitability achieved since acquisition of NCFM are reasonably likely to return to the extent that projected cash flows from the practice can substantiate the carrying value of the NCFM Medical Database.

An impairment loss is recognized if the carrying amount of a reporting unit exceeds its fair value. The amount of impairment loss is measured as the excess of the reporting unit’s carrying value over its fair value. We determined that the carrying amount of the reporting unit, which consists of the NCFM practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $716,000 to adjust carrying value of the NCFM Medical Database to its estimated fair value of $-0- in the three and nine months ended September 30, 2024.

The fair value of the NCFM reporting unit was determined using a discounted cash flow approach, which applies a market discount rate to a projected stream of cash flows, as estimated by management. As such, the fair values of the NCFM reporting unit and goodwill rely on significant unobservable inputs and assumptions and there is uncertainty in the expected future cash flows used in the impairment review.

Impairment of AEU Goodwill – 2023

During the third quarter of 2023, we determined that triggering events had occurred that required an impairment assessment of the AEU goodwill. The triggering events included (i) a material decline in revenue during third quarter 2023, and (ii) an inability of the business to achieve profitability since its acquisition. An impairment loss is recognized if the carrying amount of a reporting unit exceeds its fair value. The amount of impairment loss is measured as the excess of the reporting unit’s carrying value over its fair value. We determined that the carrying amount of the reporting unit, which consists of the AEU practice, exceeded its estimated fair value. Accordingly, we recorded an impairment charge in the amount of $319,958 to adjust carrying value of AEU goodwill to its estimated fair value of $-0- in the three and nine months ended September 30, 2023.

The fair value of the AEU reporting unit was determined using an expected present value approach, which applies a market discount rate to a probability-weighted stream of cash flows based on multiple scenarios, as estimated by management. As such, the fair values of the AEU reporting unit and goodwill rely on significant unobservable inputs and assumptions and there is uncertainty in the expected future cash flows used in the impairment review.

Liquidity and Capital Resources

Liquidity Condition

During the second quarter of 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This update provided U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. Under this standard, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period, including interim periods. In evaluating our ability to continue as a going concern, management considered the conditions and events that could raise substantial doubt about our ability to continue as a going concern within 12 months after our financial statements were issued (November 14, 2025).

Management considered our current financial condition and liquidity sources, including current funds available, forecasted future cash flows and our obligations due before November 14, 2025 and concluded that, without additional funding, we will not have sufficient funds to meet our obligations within one year from the date the consolidated financial statements were issued. Without raising additional capital, either via additional advances made pursuant to the SEPA or from other sources, there is substantial doubt about our ability to continue as a going concern through November 14, 2025. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. This basis of presentation contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business.

We are subject to a number of risks, including uncertainty related to product development and generation of revenues and positive cash flow from our Digital Healthcare Division and a dependence on outside sources of capital. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill our growth and operating activities and generating a level of revenues adequate to support our cost structure.

As of September 30, 2024, we had cash balances of $14,958, a working capital deficit of $1,982,113 and an accumulated deficit of $46,934,409. For the nine months ended September 30, 2024, we had a net loss of $4,901,273 and we used cash from operating activities of $2,750,520. We expect to continue to incur net losses and have significant cash outflows for at least the next 12 months.

Significant Liquidity Transactions

Through September 30, 2024, we have funded our operations principally through a combination of sales of our common stock, convertible and non-convertible promissory notes, government issued debt, and related party debt, as described below.

On July 5, 2022, we entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”). Pursuant to the SEPA, we have the right to sell to Yorkville up to 30,000,000 shares of our common stock, par value $0.0001 per share, at our request any time during the three-year commitment period set forth in the SEPA. Because the purchase price per share to be paid by Yorkville for the shares of common stock sold by us to Yorkville pursuant to the SEPA, if any, will fluctuate based on the market prices of our common stock during the applicable pricing period, we cannot reliably predict the actual purchase price per share to be paid by Yorkville for those shares, or the actual gross proceeds we will receive from those sales, if any. During January 2023, we sold 225,000 shares of common stock under the SEPA, receiving $18,765 in proceeds, all of which was applied to the balance of a then-outstanding promissory note payable to Yorkville. We have not sold any additional shares under the SEPA since January 2023.

During the nine months ended September 30, 2024, we issued 16 new convertible notes payable to, and received three undocumented advances from, our CEO, Dr. Michael Dent, for aggregate net cash proceeds of $2,675,000 and refinanced or extended four existing notes with an aggregate principal of $833,000. We also issued notes payable to third parties for net cash proceeds of $335,000. We made repayments on related party and third-party notes of $67,601 and $826,545, respectively.

During the nine months ended September 30, 2024, we sold 5,977,193 shares of common stock to four investors in separate private placement transactions. We received $405,000 in proceeds from the sales. In connection with the stock sales, we also issued 2,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.17 per share and 438,596 five-year warrants to purchase shares of common stock at an exercise price of $0.16 per share.

On January 17, 2023, we entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and we agreed to sell, AHP. Since the sale date, we have received the following proceeds: (1) $750,000 upon signing of the AHP Merger Agreement, (2) $31,381 in March 2023 for the Stub Period Reimbursement, ad (3) $1,750,000 ($1,540,000 net after commissions) in Incremental Cash Consideration during June, July and August for meeting participating physician transfer milestones, and $1,873,993 gross ($1,186,231 net after commissions) in October 2023 from the 2022 MSSP Consideration. We also expect to receive $500,000 ($325,000 net after payments to participating physicians and commissions) in the fourth quarter of 2024 from the Physician Advance Consideration. We may receive future proceeds comprised of proceeds from sale of shares of the Buyer if the Buyer completes an initial public offering by February 1, 2025.

Without raising additional capital, whether via additional advances made pursuant to the SEPA, from the sale of equity or debt instruments, from receipt of remaining contingent consideration related to the sale of the ACO/MSO Division, or from other sources, there is substantial doubt about the Company’s ability to continue as a going concern through November 14, 2025. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of presentation contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

Plan of operation and future funding requirements

Our plan of operations is to profitably operate our Health Services business and continue to invest in our Digital Healthcare business, including our cloud-based online personal medical information and record archiving system, the “HealthLynked Network.”

We are marketing the HealthLynked Network by targeting large health systems, hospitals and universities. In addition, we are marketing via direct-to-patient marketing, affiliated marketing campaigns, co-marketing with our Medical Distribution businesses subsidiary MOD, and expanded southeast regional sales efforts. Our initial sales strategy is utilizing Internet-based marketing to increase penetration to targeted geographical areas. These campaigns are focused on both physician practices and patient members. We also are leveraging MOD’s discounted medical supplies as an offering to our patient and physician members in the HealthLynked Network. We also intend to utilize physician telesales through the use of telesales representatives whom we will hire as access to capital allows. If we fail to complete the development of, or successfully market, the HealthLynked Network, our ability to realize future increases in revenue and operating profits could be impacted, and our results of operations and financial position would be materially adversely affected.

We plan to raise additional capital to fund our ongoing plan of operation.

Historical Cash Flows

Net cash (used in) provided by: Nine Months Ended September 30, 2024 2023
Net cash used in continuing operating activities $(2,750,520) $(2,867,628)
Net cash used in discontinued operating activities --- (84,946)
Net cash used in operating activities (2,750,520) (2,952,574)
Net cash provided by (used in) continuing investing activities (2,598) 2,319,881
Net cash provided by (used in) discontinued investing activities --- ---
Net cash provided by (used in) investing activities (2,598) 2,319,881
Net cash provided by continuing financing activities 2,520,854 622,130
Net cash provided by discontinued financing activities --- ---
Net cash provided by financing activities 2,520,854 622,130
Net increase (decrease) in cash from continuing operating (232,264) 74,383
Net (decrease) in cash from discontinued operating --- (84,946)
Net increase (decrease) in cash $(232,264) $(10,563)

Operating Activities – During the nine months ended September 30, 2024, we used cash from operating activities of $2,750,520, as compared with $2,952,574 in the nine months ended September 30, 2023. The slight decrease in cash usage results primarily cost reduction efforts at our Health Services practices an corporate offices and a decrease of $84,946 in cash used in operations of our discontinued ACO/MSO Division resulting from the unit being sold on January 17, 2023

Investing Activities – During the nine months ended September 30, 2024, we used $2,598 in investing activities related to acquisition of computers and office equipment. During the nine months ended September 30, 2023, we realized $2,319,881 from investing activities, comprised mostly of $2,321,381 cash proceeds received form the AHP sale.

Financing Activities – During the nine months ended September 30, 2024, cash provided by financing activities was $2,520,854, comprised of $405,000 from the sale of common stock, $2,675,000 from the issuance of notes payable to related parties, and $335,000 from the issuance of notes payable to third parties, offset by $67,601 repayments made against notes payable balances to related and third parties. During the nine months ended September 30, 2023, cash provided by financing activities was comprised of $475,000 proceeds from the sale of common stock (net of $18,765 received from sales of common stock under the SEPA that were applied to the balance of the Note Payable) and $1,733,750 from the issuance of notes payable, offset by $1,586,620 repayments made against notes payable balances (net of $18,765 received from sales of common stock under the SEPA that were applied to the balance of the Note Payable).

Exercise of Warrants and Options

No warrants or options were exercised during the nine months ended September 30, 2024 or 2023.

Other Outstanding Obligations at September 30, 2024

As of September 30, 2024, 105,596,579 shares of our common stock are issuable pursuant to the exercise of warrants with exercise prices ranging from $0.035 to $1.05.

As of September 30, 2024, 6,246,917 shares of our common stock are issuable pursuant to the exercise of options with exercise prices ranging from $0.0569 to $0.263.

As of September 30, 2024, 2,649,203 shares of our common stock are earned but unissued pursuant to consulting and director agreements.

As of September 30, 2024, 53,870,658 shares of our common stock are issuable upon the conversion of outstanding convertible notes payable at the option of the beneficial holder of those instruments, Dr. Michael Dent.

Off Balance Sheet Arrangements

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable Securities and Exchange Commission rules.

Market risk

As filed, 149 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 229.10(f)(1).

Controls and procedures

As filed, 1,707 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of September 30, 2024 based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, and in light of the material weaknesses found in our internal controls over financial reporting, our management concluded that our disclosure controls and procedures were not effective as of September 30, 2024.

Changes in Internal Control over Financial Reporting

There was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the fiscal quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 149 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is not required to provide the information required by this item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-07-01 to 2024-09-30$590.1kus-gaap:Revenues
Revenue9 months2024-01-01 to 2024-09-30$2.4mus-gaap:Revenues
Selling, general and administrative3 months2024-07-01 to 2024-09-30$631.8kus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2024-01-01 to 2024-09-30$2.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2024-07-01 to 2024-09-30−$1.7mus-gaap:OperatingIncomeLoss
Operating income9 months2024-01-01 to 2024-09-30−$3.9mus-gaap:OperatingIncomeLoss
Net income3 months2024-07-01 to 2024-09-30−$2.0mus-gaap:NetIncomeLoss
Net income9 months2024-01-01 to 2024-09-30−$4.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-07-01 to 2024-09-30−$0.01us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2024-01-01 to 2024-09-30−$0.02us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-07-01 to 2024-09-30−$0.01us-gaap:EarningsPerShareBasic
Basic EPS9 months2024-01-01 to 2024-09-30−$0.02us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-07-01 to 2024-09-30281,947,151 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2024-01-01 to 2024-09-30281,428,579 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2024-01-01 to 2024-09-30−$2.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2024-01-01 to 2024-09-30$2.6kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2024-09-30$15.0kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-09-30$1.8mus-gaap:AssetsCurrent
Total assetsAt period end2024-09-30$2.8mus-gaap:Assets
Current liabilitiesAt period end2024-09-30$3.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-09-30$4.7mus-gaap:Liabilities
Shareholders' equityAt period end2024-09-30−$1.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-24-098383. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.